Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Multiple myeloma in 2016

Fresh perspectives on treatment and moments of clarity

Nature Reviews Clinical Oncology volume 14, pages 73–74 (2017)Cite this article

Subjects

Data obtained in the past year underscored the benefit of a triplet regimen comprising bortezomib, lenalidomide, and dexamethasone for patients with newly-diagnosed multiple myeloma, and have provided high-level evidence supporting the safety of adding daratumumab to standard-of-care doublets for those with relapsed and/or refractory disease. As a result, achieving minimal residual disease-negativity at any stage of myeloma is now a realistic possibility.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Durie, B. G. et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet http://dx.doi.org/10.1016/S0140-6736(16)31594-X (2016).

  2. Palumbo, A. et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 754–766 (2016).

    Article  CAS  Google Scholar 

  3. Dimopoulos, M. A. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 1319–1331 (2016).

    Article  CAS  Google Scholar 

  4. Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328–e346 (2016).

    Article  Google Scholar 

  5. Paiva, B., van Dongen, J. J. & Orfao, A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood 125, 3059–3068 (2015).

    Article  CAS  Google Scholar 

  6. Rajkumar, S. V. & Harousseau, J. L. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood 128, 2757–2764 (2016).

    Article  CAS  Google Scholar 

  7. Benboubker, L. et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N. Engl. J. Med. 371, 906–917 (2014).

    Article  CAS  Google Scholar 

  8. Rajkumar, S. V. & Kyle, R. A. Progress in myeloma — a monoclonal breakthrough. N. Engl. J. Med. 375, 1390–1392 (2016).

    Article  Google Scholar 

  9. Lonial, S. et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387, 1551–1560 (2016).

    Article  CAS  Google Scholar 

  10. Moreau, P. & Rajkumar, S. V. Multiple myeloma — translation of trial results into reality. Lancet 388, 111–113 (2016).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Prashant Kapoor and S. Vincent Rajkumar are at the Division of Hematology, Mayo Clinic, 200 First Street South West, Rochester, Minnesota 55905, USA.,

    Prashant Kapoor & S. Vincent Rajkumar

Authors
  1. Prashant Kapoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Vincent Rajkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Vincent Rajkumar.

Ethics declarations

Competing interests

P.K. has received research funding from Amgen, Celgene, and Takeda. S.V.R. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kapoor, P., Rajkumar, S. Fresh perspectives on treatment and moments of clarity. Nat Rev Clin Oncol 14, 73–74 (2017). https://doi.org/10.1038/nrclinonc.2016.221

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2016.221

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing